WaveMan
WaveMan · Company
STOK · Stoke Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

STOK Stoke Therapeutics (STOK) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001623526
Quote by TradingView
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
111
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $0 priced

What the filings say about STOK

Insiders, 180 days
-$1.5M net sold
3 sellers · 24% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$39.0M
3 notices

Stoke Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Stoke Therapeutics, Inc. insiders sold a net $1.5M of stock across 176 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Allan Jonathan
GENERAL COUNSEL & CORP SEC
SELL
2026-10-02 SEC
627
$16.5K
+0.6%
Context
  • 37 earlier Form 4 trades (code P or S) here by this insider (37 sales), the last on Aug 18, 2026.
  • The trade is 3.0% of the 20,598 shares held after it.
  • 1 other insider sold within 30 days.
  • 111 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: GENERAL COUNSEL & CORP SEC Allan Jonathan sold about $16.5K of STOK under a 10b5-1 plan on Oct 2, 2026; 1 other insider sold within 30 days and 111 funds added in the latest 13F quarter.
Ticho Barry
CHIEF MEDICAL OFFICER
SELL
2026-10-02 SECtraded 2026-10-01
1,051
$27.5K
+0.6%
Context
  • 70 earlier Form 4 trades (code P or S) here by this insider (70 sales), the last on Sep 1, 2026.
  • The trade is 5.5% of the 19,059 shares held after it.
  • 1 other insider sold within 30 days.
  • 111 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MEDICAL OFFICER Ticho Barry sold about $27.5K of STOK under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 111 funds added in the latest 13F quarter.
Ticho Barry
CHIEF MEDICAL OFFICER
SELL
2026-09-03 SECtraded 2026-09-01
3,945
$120.4K
-14.6%
Context
  • 68 earlier Form 4 trades (code P or S) here by this insider (68 sales), the last on Aug 18, 2026.
  • The trade is 18.2% of the 21,710 shares held after it.
  • 2 other insiders sold within 30 days.
  • 111 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MEDICAL OFFICER Ticho Barry sold about $120.4K of STOK under a 10b5-1 plan on Sep 1, 2026; 2 other insiders sold within 30 days and 111 funds added in the latest 13F quarter.
Ticho Barry
CHIEF MEDICAL OFFICER
SELL
2026-09-03 SECtraded 2026-09-01
1,600
$49.7K
-14.6%
Context
  • 68 earlier Form 4 trades (code P or S) here by this insider (68 sales), the last on Aug 18, 2026.
  • The trade is 8.0% of the 20,110 shares held after it.
  • 2 other insiders sold within 30 days.
  • 111 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MEDICAL OFFICER Ticho Barry sold about $49.7K of STOK under a 10b5-1 plan on Sep 1, 2026; 2 other insiders sold within 30 days and 111 funds added in the latest 13F quarter.
Allan Jonathan
GENERAL COUNSEL & CORP SEC
SELL
2026-08-18 SEC
2,716
$86.9K
-22.9%
Context
  • 35 earlier Form 4 trades (code P or S) here by this insider (35 sales), the last on Jun 16, 2026.
  • The trade is 12.7% of the 21,370 shares held after it.
  • 2 other insiders sold within 30 days.
  • 111 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: GENERAL COUNSEL & CORP SEC Allan Jonathan sold about $86.9K of STOK on Aug 18, 2026; 2 other insiders sold within 30 days and 111 funds added in the latest 13F quarter.
176 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 171 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.5M over 180 days
-$1.1M over 90 days
below 66% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
111 funds bought in last quarter
more than 72% of Pharma & Biotech
Revenue
+404.5% year over year
more than 92% of Pharma & Biotech
Margin
-3.7% net margin
more than 71% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
22.5% of the float short (float per yahoo 2026-10-27) · 12.3 days to cover · settled 2026-10-15
more than 87% of Pharma & Biotech
What changed in the last 30 days
Oct 21Former Affiliate EDWARD KAYE filed to sell $38.4M by Oct 21 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 2CHIEF MEDICAL OFFICER Ticho Barry sold $27.5K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 2GENERAL COUNSEL & CORP SEC Allan Jonathan sold $16.5K under a 10b5-1 plan (Oct 2)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 2Officer JONATHAN D ALLAN filed to sell $16.3K by Oct 2 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch STOK

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-19.7%12M
-29%-13%+4%+21%2025-102025-122026-022026-042026-062026-082026-10 2026-03-10 · Krainer Adrian R. sold $1.3M2025-11-24 · Krainer Adrian R. sold $1.2M2025-11-14 · Krainer Adrian R. sold $565.4K2025-11-14 · Krainer Adrian R. sold $526.6K2026-08-18 · Kaye Edward M. MD sold $381.8K2026-03-20 · Allan Jonathan sold $292.4K2026-03-02 · Krainer Adrian R. sold $286.7K2025-12-08 · Kaye Edward M. MD sold $269.1K2026-07-01 · Ticho Barry sold $219.4K2025-12-05 · Kaye Edward M. MD sold $199.5K2026-03-18 · Ticho Barry sold $190.8K2026-03-10 · TZIANABOS ARTHUR sold $174.2K2026-08-03 · Ticho Barry sold $171.0K2025-12-05 · Allan Jonathan sold $169.0K2025-12-04 · Kaye Edward M. MD sold $160.6K2026-08-18 · Ticho Barry sold $144.8K2026-03-18 · Allan Jonathan sold $132.1K2026-09-01 · Ticho Barry sold $120.4K2025-12-08 · Kaye Edward M. MD sold $120.3K2026-03-17 · Ticho Barry sold $117.1K2025-11-03 · Ticho Barry sold $95.2K2025-12-08 · Allan Jonathan sold $87.3K2026-08-18 · Allan Jonathan sold $86.9K2026-03-17 · Ticho Barry sold $86.4K2026-03-17 · Allan Jonathan sold $81.1K2025-12-05 · Allan Jonathan sold $74.4K2026-05-01 · Ticho Barry sold $73.5K2026-03-18 · Leggett Thomas sold $68.0K2025-12-05 · Ticho Barry sold $62.4K2026-04-01 · Ticho Barry sold $60.0K2026-03-17 · Allan Jonathan sold $59.8K2026-03-18 · Hoitt Jason sold $55.1K2026-06-01 · Ticho Barry sold $54.9K2025-12-05 · Ticho Barry sold $52.4K2025-12-05 · Kaye Edward M. MD sold $52.4K2026-09-01 · Ticho Barry sold $49.7K2025-12-08 · Kaye Edward M. MD sold $44.1K2026-03-19 · Ticho Barry sold $43.8K2026-06-16 · Allan Jonathan sold $43.6K2025-12-03 · Allan Jonathan sold $43.0K2025-12-04 · Ticho Barry sold $42.2K2025-12-02 · Allan Jonathan sold $41.9K2026-10-21 · EDWARD KAYE filed to sell $38.4M2026-10-02 · JONATHAN D ALLAN filed to sell $16.3K2026-08-03 · BARUCH TICHO filed to sell $605.1K2026-07-01 · BARUCH S. TICHO filed to sell $236.5K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns STOK: institutional holders (13F)

13F holdings, latest reported quarter
Lynx1 Capital Management LP
8,076,808 sh
$264.3M
BlackRock, Inc.
5,877,357 sh
$192.3M
RTW INVESTMENTS, LP
5,623,525 sh
$184.0M
FMR LLC
5,313,100 sh
$173.8M
Redmile Group, LLC
3,945,920 sh
$129.1M

Congress trades in STOK

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

STOK planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
EDWARD KAYE
Filed 2026-10-21
$38.4M
JONATHAN D ALLAN
Filed 2026-10-02
$16.3K
BARUCH TICHO
Filed 2026-08-03
$605.1K
BARUCH S. TICHO
Filed 2026-07-01
$236.5K

STOK mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
First Trust Dow Jones Select MicroCap Index Fund
$6.1M position · as of 2026-06-30
2.3%
Global X Genomics & Biotechnology ETF
$810.8K position · as of 2026-05-31
1.5%
Franklin Genomic Advancements ETF
$371.3K position · as of 2026-06-30
1.3%
Fidelity Disruptive Medicine ETF
$484.4K position · as of 2026-05-31
1.2%
ALPS Medical Breakthroughs ETF
$1.8M position · as of 2026-05-31
1.1%
Harbor Active Small Cap Growth ETF
$294.6K position · as of 2026-07-31
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 2
1 active
1
Phase 3
1 active
1
Multi-phase
0 active
What changed recently
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen i
2026-10-21 · Recruiting → Active Not Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Edward MKaye Md
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$5.6M
$7.5M
$3.5M
+20%
n/a
2023
$3.5M
$1.1M
$1.6M
-43%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.5M sold by insiders over 180 days, 111 funds added last quarter, $39.0M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

STOK financials

Revenue growth
+404.5%
XBRL, annual
Net margin
-3.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$27.6M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-753.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$180.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-61.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-53.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-64.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-11.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$184.4M$36.6M$8.8M$12.4M
Operating income-$20.6M-$101.4M-$114.8M-$104.4M
Net income-$6.9M-$89.0M-$104.7M-$101.1M
EPS (diluted)-0.12-1.65-2.38-2.60
Operating cash flow$45.6M-$86.9M-$81.1M-$31.9M
Cash$84.2M$128.0M$191.4M$113.6M
SEC XBRL, fiscal years, as known on 2026-10-28

STOK Stock Sonar score 5/7 axes

Find similar shapesCompare

STOK ranks highest on growth (92nd percentile) and institutional and government (53rd), and lowest on insider conviction (16th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
43
Inputs
  • Return on equity-61.1% · 47 pct, sector of 545
  • Return on assets-53.4% · 42 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-64.0% · 39 pct, sector of 576
Growth
92
Inputs
  • Revenue growth, YoY+404.5% · 92 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
16
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.3M · 33 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
53
Inputs
  • Funds adding, latest quarter111 · 72 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$160K · 33 pct, sector of 133
Risk and compliance
46
Inputs
  • Short interest, % of float+25.2% · 8 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+4.6% · 85 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

STOK filings, in plain words

Are Stoke Therapeutics insiders buying or selling STOK?

In the 180 days to 2026-10-28, Stoke Therapeutics insiders were net sellers, a net $1.5M across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of STOK?

Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $39.0M of stock; the latest, by EDWARD KAYE, was filed 2026-10-21.

Read the full summary

In the 180 days to 2026-10-28, Stoke Therapeutics insiders were net sellers of STOK, a net $1.5M across purchases and sales reported on Form 4 by 3 sellers. 24% of the 17 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $39.0M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies